136 related articles for article (PubMed ID: 8476501)
1. Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression.
Perlaky L; Saijo Y; Busch RK; Bennett CF; Mirabelli CK; Crooke ST; Busch H
Anticancer Drug Des; 1993 Feb; 8(1):3-14. PubMed ID: 8476501
[TBL] [Abstract][Full Text] [Related]
2. Increased growth of NIH/3T3 cells by transfection with human p120 complementary DNA and inhibition by a p120 antisense construct.
Perlaky L; Valdez BC; Busch RK; Larson RG; Jhiang SM; Zhang WW; Brattain M; Busch H
Cancer Res; 1992 Jan; 52(2):428-36. PubMed ID: 1728415
[TBL] [Abstract][Full Text] [Related]
3. Cellular pharmacology of p120 antisense oligodeoxynucleotide phosphorothioate ISIS 3466.
Saijo Y; Perlaky L; Valdez BC; Wang H; Henning D; Busch H
Oncol Res; 1993; 5(8):283-91. PubMed ID: 8012060
[TBL] [Abstract][Full Text] [Related]
4. A region of antisense RNA from human p120 cDNA with high homology to mouse p120 cDNA inhibits NIH 3T3 proliferation.
Valdez BC; Perlaky L; Saijo Y; Henning D; Zhu C; Busch RK; Zhang WW; Busch H
Cancer Res; 1992 Oct; 52(20):5681-6. PubMed ID: 1394192
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
6. Nucleolar protein P120 and its targeting for cancer chemotherapy.
Busch H; Busch RK; Freeman JW; Perlaky L
Boll Soc Ital Biol Sper; 1991 Aug; 67(8):739-50. PubMed ID: 1809302
[TBL] [Abstract][Full Text] [Related]
7. Nucleolar and nuclear aberrations in human lox tumor cells following treatment with p120 antisense oligonucleotide ISIS-3466.
Perlaky L; Smetana K; Busch RK; Saijo Y; Busch H
Cancer Lett; 1993 Oct; 74(1-2):125-35. PubMed ID: 8287366
[TBL] [Abstract][Full Text] [Related]
8. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.
Bennett CF; Chiang MY; Chan H; Shoemaker JE; Mirabelli CK
Mol Pharmacol; 1992 Jun; 41(6):1023-33. PubMed ID: 1352033
[TBL] [Abstract][Full Text] [Related]
9. Effect of nucleolar P120 expression level on the proliferation capacity of breast cancer cells.
Fonagy A; Swiderski C; Ostrovsky AM; Bolton WE; Freeman JW
Cancer Res; 1994 Apr; 54(7):1859-64. PubMed ID: 8137301
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo.
Nakashiro K; Kawamata H; Hino S; Uchida D; Miwa Y; Hamano H; Omotehara F; Yoshida H; Sato M
Cancer Res; 1998 Feb; 58(3):549-55. PubMed ID: 9458104
[TBL] [Abstract][Full Text] [Related]
11. Antisense phosphorothioate oligonucleotides direct both site-specific and nonspecific RNAse H cleavage of in vitro synthesized p120 mRNA.
Weidner DA; Busch H
Oncol Res; 1994; 6(6):237-42. PubMed ID: 7865899
[TBL] [Abstract][Full Text] [Related]
12. Reversible inhibition of IL-8 receptor B mRNA expression and proliferation in non-small cell lung cancer by antisense oligonucleotides.
Olbina G; Cieslak D; Ruzdijic S; Esler C; An Z; Wang X; Hoffman R; Seifert W; Pietrzkowski Z
Anticancer Res; 1996; 16(6B):3525-30. PubMed ID: 9042216
[TBL] [Abstract][Full Text] [Related]
13. Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase.
Berg RW; Werner M; Ferguson PJ; Postenka C; Vincent M; Koropatnick DJ; Behrend E
J Pharmacol Exp Ther; 2001 Aug; 298(2):477-84. PubMed ID: 11454908
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
Saijo Y; Perlaky L; Wang H; Busch H
Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines.
Lee CT; Wu S; Gabrilovich D; Chen H; Nadaf-Rahrov S; Ciernik IF; Carbone DP
Cancer Res; 1996 Jul; 56(13):3038-41. PubMed ID: 8674059
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
Cucco C; Calabretta B
Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
[TBL] [Abstract][Full Text] [Related]
18. Antisense-mediated specific inhibition of P120 protein expression prevents G1- to S-phase transition.
Fonagy A; Swiderski C; Dunn M; Freeman JW
Cancer Res; 1992 Oct; 52(19):5250-6. PubMed ID: 1394129
[TBL] [Abstract][Full Text] [Related]
19. Antisense inhibition of parathyroid hormone-related peptide gene expression reduces malignant pituitary tumor progression and metastases in the rat.
Akino K; Ohtsuru A; Yano H; Ozeki S; Namba H; Nakashima M; Ito M; Matsumoto T; Yamashita S
Cancer Res; 1996 Jan; 56(1):77-86. PubMed ID: 8548779
[TBL] [Abstract][Full Text] [Related]
20. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
